Genase Therapeutics
Genase Therapeutics is advancing a new generation of DHODH inhibitors, targeting a key enzyme involved in cell proliferation and mitochondrial metabolism. Its lead candidate, based on discoveries from Karolinska Institute, is now preparing for IND-enabling studies.

Gilbert
Dutch medtech company Gilbert is advancing inhaled therapy with its Smart Precision Inhaler, a next-generation platform designed for highly precise delivery of advanced pharmaceutical compounds. The scalable system combines dosing accuracy with patient-friendly usability, creating new opportunities for inhaled therapies that require both precision and flexibility.

JAMA Therapeutics
As a spin-off from University Medical Center Utrecht, JAMA Therapeutics is developing cell-derived nanoparticle delivery platforms for cardiac gene therapy. Its approach aims to improve delivery of RNA, proteins, and programmable gene editors to heart tissue, opening new possibilities for inherited cardiomyopathy treatment.

Juvant Medical
Juvant Medical is transforming surgical oncology through real-time tissue identification. Its SmartScan platform enables surgeons to distinguish tumor tissue during breast cancer surgery with over 90% accuracy, allowing immediate margin assessment and reducing the likelihood of repeat procedures.

Myriagon
Myriagon is addressing one of oncology’s major unmet needs: chemotherapy-induced peripheral neuropathy. Its lead compound, a patented oral MAGL inhibitor, has shown full pain relief in preclinical models without physical dependence. With no approved treatments currently available for CIPN, the company’s non-addictive analgesic platform could offer an important alternative to opioid-based care.

OncoInv
OncoInv is expanding access to structured cancer detection through OncoSeek®, a validated multi-cancer detection platform covering nine high-impact cancer types. By partnering with local distributors and clinical providers, the company brings advanced cancer screening to underserved healthcare markets worldwide.

Revividal
Revividal is developing an ingestible gastric medical device designed to support satiety through mechanoreceptor activation. By avoiding systemic drugs and invasive surgery, the company offers a novel approach to weight-loss support within the growing metabolic health market.

SLAM Orthopedic
Founded by a trauma surgeon, SLAM Orthopedic develops smart surgical instruments that help surgeons choose the correct implant during fracture repair. Its sensor-based platform provides real-time data on bone quality and implant positioning, with the aim of reducing complications and improving operating room efficiency.

Wavefront Therapeutics
Wavefront Therapeutics focuses on myocardial ischemia with intracellular peptide therapies designed for cardiac arrest and reperfusion injury. Supported by preclinical validation in porcine models, its lead assets target acute cardiac events where current treatment options remain limited.

A Platform for Future Innovation

The nine finalists highlighted the diversity of today’s health innovation landscape: from precision medicine and gene therapy to smart surgical tools and next-generation diagnostics. Together, they reflect the scientific ambition and entrepreneurial energy driving the sector forward.

Start-ups aiming to take the stage next year can already look ahead: the next editions of Innovation for Health and the Global Investor Forum will take place on 10–11 March 2027 in Utrecht, offering new opportunities to connect with investors, partners, and the wider life sciences ecosystem.